A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

NCT05198804

Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (industry) · ZNTL — their whole pipeline →.

Phase

Phase 1/2

Status

Completed

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

117actual

Sites

Countries

France, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-01-27

actual

When the study began enrolling

Primary completion

2025-10-15

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-01-19

actual

The whole study's end, after follow-up

First posted

2022-01-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Ovarian Cancer
Platinum-resistant Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions

Drug: Azenosertib — also filed as ZN-c3
Drug: Niraparib

Primary outcomes

what the primary-completion date above is the date OF

To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2D

measured 6 months

To determine the safety and tolerability of ZN-c3 monotherapy

measured 12 months

To investigate the antitumor activity of ZN-c3 monotherapy

measured 12 months

Permalink · ZNTL's whole pipeline · Catalyst calendar · Every registered study · What changed